Published

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: The American journal of psychiatry
Date: 2025-01-01
Source: PubMed
DOI: 10.1176/appi.ajp.20231063
PubMed: 39741440

Authors

Aaronson ST van der Vaart A Miller T LaPratt J Swartz K Shoultz A Lauterbach M Suppes T Sackeim HA

Watch author

Derived topics and classifications

psilocybin Depression PTSD Pharmacology Treatment-Resistant Depression Safety Drug Interactions Other

Citation graph

0 referenced DOIs found in stored source metadata. 7 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement2026-12-01 Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13 Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01 Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial2026-06-01 Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications2026-04-01 Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention2026-03-01 Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.2025-01-01

Related papers

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06